Golde Named Physician-in Chief at Memorial Hospital

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 23 No 5
Volume 23
Issue 5

NEW YORK--Dr. David W. Golde has been appointed Physician-in-Chief of Memorial Hospital, Dr. Paul Marks, president of Memorial Sloan-Kettering Cancer Center, announced. Dr. Golde succeeds Joseph V. Simone, MD, who is to become clinical director for the Huntsman Cancer Institute, Salt Lake City.

NEW YORK--Dr. David W. Golde has been appointed Physician-in-Chiefof Memorial Hospital, Dr. Paul Marks, president of Memorial Sloan-KetteringCancer Center, announced. Dr. Golde succeeds Joseph V. Simone,MD, who is to become clinical director for the Huntsman CancerInstitute, Salt Lake City.

Dr. Golde was head of the Cancer Center's Division of HematologicOncology, Department of Medicine, as well as head of the Laboratoryof Molecular and Cellular Hematology at the Sloan-Kettering Institute.He is renowned for his contributions to the understanding of normaland leukemic blood cell growth. His demonstration that certainwhite blood cells produce colony-stimulating factors in humanslaid the groundwork for the isolation of these factors.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content